REFRACTORY COLORECTAL CARCINOMA
Clinical trials for REFRACTORY COLORECTAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY COLORECTAL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY COLORECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test could help pick the right drug for tough colorectal cancers
Disease control OngoingThis phase II trial is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose between two standard drugs—regorafenib or TAS-102—for people with advanced colorectal cancer that has stopped responding to other treatments. The study will enroll 100 par…
Matched conditions: REFRACTORY COLORECTAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant colorectal cancer?
Disease control TerminatedThis trial is testing whether combining two standard drugs—fruquintinib and TAS-102—can help people with metastatic colorectal cancer that has stopped responding to at least two prior chemotherapy regimens. The study will measure how long patients live without the disease getting…
Matched conditions: REFRACTORY COLORECTAL CARCINOMA
Sponsor: Fudan University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…
Matched conditions: REFRACTORY COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC